ArticleNew microbes and new infections2026
The incidence and outcomes of hospital acquired- bloodstream infection and ventilator associated pneumonia and the impact of infectious diseases referral using data from the clinically-oriented antimicrobial resistance surveillance network for healthcare-associated infections (ACORN-HAI): An interim report.
Article in New microbes and new infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To determine the incidence of hospital-acquired bloodstream infections (BSI), Ventilator-Associated Pneumonias (VAP) and the impact of Infectious Diseases (ID) referral on outcomes using data from the ACORN HAI surveillance network. Methods: Adults hospitalized ≥48 h in a tertiary hospital (3/2023-3/2024) were prospectively included if HA-BSI and VAP criteria were met. ID referral was defined as formal referral to, or consultation with an ID specialist. Clinical, laboratory parameters, and 28-day outcomes were collected. The incidence of HA-BSI and VAP was calculated using the number of patients with HA-BSI or VAP as numerator, and total hospitalized adult patients as denominator; incidence density per 1000 patient-days was computed using infection episodes as numerator, and total patient-days as denominator. Results: Among 115 patients (mean age 62.4 ± 18.1 years), 58.3% were male, and 33. 91% diabetic. HA-BSI incidence density was higher compared to VAP (1.03 vs. 46 per 1000 patient-days). Mortality (BSI 24.7%, VAP 50%, combined infection 57.1%) differed across infection types. Majority of infection episodes were referred to ID (119/143, 83.21%). Although late referrals (9/143, 6.29%), had numerically higher mortality and prolonged hospitalization, these were not statistically significant. The timing of ID referral had no statistically significant association with clinical and functional outcomes, mortality, and length of stay. Conclusion: Overall HA-BSI and VAP rates were low, but still associated with high mortality and prolonged hospitalization. ID referral was not associated with better outcomes in this small study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.